Press Release: Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media Release COPENHAGEN, Denmark; December 7, 2024 Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The results demonstrated an overall response rate…
Thu, 01 May 2025 17:26:00 GMT Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ... investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Cytokine release ...
